Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.
Prostate Cancer
RADIATION: < 15% risk of + LN|RADIATION: > 15% risk of + LN
Acute Grade 3 or Higher Treatment-related Toxicity Rate., Number of participants that experienced acute grade 3 or higher, treatment-related toxicity based on CTCAE version 3.0 criteria., 6 months after the completion of radiation therapy
Collect and Analyze Quality of Life, Treatment-related Late Morbidity, Disease Control, and Survival Outcome Parameters., After radiation: every 6 months for 3 years, then annually for 20 years|Collect and Analyze Treatment, Biologic and Diagnostic Information That May Impact Quality of Life, Disease Control, Morbidity and/or Survival Outcomes., After radiation: every 6 months for 3 years, then annually for 20 years
The purpose of this study is to see what effects, good and/or bad, proton based radiation combined with low dose chemotherapy and hormonal therapy, has on patients and their cancer.